Imagine that it’s the year 2025. In locker rooms across the NFL, as ankles are taped and braces strapped on, trainers hand out gel capsules for players to ingest minutes before they take the field. The capsules are scientifically designed to protect against the deleterious effect of concussive blows to the head and traumatic brain injury—and, as a result, they have helped to sustain the viability of the sport of football. Oh, and yeah, they are derived from marijuana.
That’s the bet those at Kannalife Sciences are making about our future reality. Kannalife is an independent pharmaceutical company that has entered into a burgeoning, and lucrative, new industry: the study of the cannabis plant and its chemical constituents for therapeutic value. They believe they have found something, something still relatively unknown and very much in its nascent stages, yet something they say has shown great promise as a neuroprotectant. Something that could change the landscape of how brain injuries of all varieties—from chronic traumatic encephalopathy (CTE) to Alzheimer’s and Parkinson’s—will eventually be treated.
“We’re pushing the boundaries on this whole industry focusing on cannabinoids,” Kikis says. “We think this is going to be the new wave of medicine.”
To read the whole article, please click here.